NeoVax(MI) vaccine developed by Dana-Farber Cancer Institute could be approved soon with promising results in boosting immune response in melanoma patients
Lara Maior
Health
Vyacheslav Lopatin / Alamy / Profimedia
Always see our news on Google
The clinical trial of the personalized vaccine NeoVax(MI) has shown promising results in the treatment of melanoma, generating a strong immune response. The vaccine contains patient-specific neoantigens and is administered together with standard immunotherapies such as nivolumab and ipilimumab. Scientists observed an increase in immune cells after vaccination, indicating effective immune activation. This innovative approach could significantly improve treatments for skin cancer.
Sources
Vaccinul contra unui tip agresiv de cancer, la un pas de a intra pe piață. Rezultatele remarcabile dau speranțe pacienților
Consiliul Concurenței analizează tranzacţia prin care Mehiläinen Oy preia rețeaua de centre mediale Regina Maria
Consiliul Concurenţei analizează preluarea Grupului Regina Maria de către Mehiläinen Oy
Latest News
12:41
India proposes extending tax incentives for foreign companies that supply equipment to local manufacturers until 2041, a measure considered beneficial for Apple.
12:40
The European fund for expanding technology companies starts investments, with an interest of 5 billion euros
12:37
Romania joins the Carpathian Initiative for regional cooperation, launched by Volodymyr Zelensky
12:36
Cristian Bușoi, Secretary of State in the Ministry of Energy, stated that the supply of fuels has improved compared to two weeks ago.
12:35
Denmark has extended mandatory military service from four to 11 months, in the context of European security / The Princess of Denmark enlists in the army at 19 years old
See more news
NEWS ON THE SAME TOPICS
.webp)
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
